Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.46 |
| ▸ | CHRNA2 | Q15822 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.46 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | HTR3B | O95264 | 1/20 | 0.46 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.46 |
| ▸ | CHRNG | P07510 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6582951 | 1.00 | ALDH1A1 (0.46) | ALDH1A1CHRNA7CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL6583004 | 0.80 | KDM4E (0.48) | ALDH1A1CHRNA7CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL6583010 | 0.80 | KDM4E (0.48) | ALDH1A1CHRNA7CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL6583042 | 0.79 | CHRNB4 (0.55) | ALDH1A1CHRNA7CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL6583046 | 0.79 | CHRNB4 (0.55) | ALDH1A1CHRNA7CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL6818552 | 0.75 | GRM5 (0.47) | — | |
| SCHEMBL6959278 | 0.75 | CHRNA3 (0.64) | ALDH1A1CHRNA7CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL10220425 | 0.74 | ALDH1A1 (0.54) | ALDH1A1CHRNA7CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL30363349 | 0.74 | ALDH1A1 (0.56) | ALDH1A1CHRNA7CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL419658 | 0.74 | ALDH1A1 (0.56) | ALDH1A1CHRNA7CHRNB2CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1079860-B1 | NICOTINE IMMUNOGEN | INDEPENDENT PHARMACEUTICA AB (SE) | 2004-10-27 | — | — | EP | disclosed |
| EP-1265888-B1 | METHOD OF PRODUCING 6-SUBSTITUTED ( S )-NICOTINE DERIVATIVES AND INTERMEDIATE COMPOUNDS | INDEPENDENT PHARMACEUTICA AB (SE) | 2004-08-11 | — | — | EP | disclosed |
| US-6747156-B2 | Method of producing 6-substituted (s)-nicotine derivatives and intermediate compounds | INDEPENDENT PHARMACEUTICA AB (SE) | 2004-06-08 | — | — | US | disclosed |
| US-6656469-B1 | Treatment of nicotine dependence from tobacco products | INDEPENDENT PHARMACEUTICA AB (SE) | 2003-12-02 | — | — | US | disclosed |
| US-20030187270-A1 | Method of producing 6-substituted (s)-Nicotine derivatives and intermediate compounds | INDEPENDENT PHARMACEUTICA AB (SE) | 2003-10-02 | — | — | US | disclosed |
| EP-1265888-A1 | METHOD OF PRODUCING 6-SUBSTITUTED ( i S /i )-NICOTINE DERIVATIVES AND INTERMEDIATE COMPOUNDS | Independent pharmaceutica AB (SE) | 2002-12-18 | — | — | EP | disclosed |
| WO-2001070730-A1 | METHOD OF PRODUCING 6-SUBSTITUTED (S)-NICOTINE DERIVATIVES AND INTERMEDIATE COMPOUNDS | INDEPENDENT PHARMACEUTICA AB (SE) | 2001-09-27 | — | — | WO | disclosed |
| EP-1079860-A1 | NICOTINE IMMUNOGEN | Independent pharmaceutica AB (SE) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999061054-A1 | NICOTINE IMMUNOGEN | INDEPENDENT PHARMACEUTICA AB (SE) | 1999-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187270-A1 | Method of producing 6-substituted (s)-Nicotine derivatives and intermediate compounds | SMOX, SLC1A5, SLC43A1 | ALDH1A1 1132/4885CHRNA7 121/4885CHRNB2 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.